Navigation Links
Imprimis to Begin New Study of Its Topical Analgesic Drug

SOLANA BEACH, Calif., Sept. 19, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:OTCQB) today announced the initiation of a clinical study of Impracor™, a topical cream that delivers a dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study will measure the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different "real world' conditions, including normal activities, heat exposure to the application site and exercising on a treadmill. The amount of the drug in the bloodstream after taking an oral dose of ketoprofen will also be studied in healthy volunteers.

Impracor is designed to be applied to the site of muscle or joint pain, delivering a clinical dose of the active drug ketoprofen in its proprietary topical-delivery platform Accudel™ to the affected area. Current prescription ketoprofen (a non-steroidal anti-inflammatory drug, NSAID) is only available in an oral formulation in the US and is used to relieve pain and inflammation in various musculoskeletal conditions. Topical delivery of NSAIDs is recognized as safe pain medication that significantly reduces side effects, especially less stomach irritation, cardiac or liver problems compared with NSAIDs taken by mouth.

Imprimis believes its patented topical-delivery platform Accudel™ can also serve as a delivery vehicle for other medications.  Going forward, the company plans to employ a strategy of repurposing or reformatting existing FDA-approved generic drugs to be used in combination with Imprimis's delivery platform to create entirely new medications to address unmet therapeutic applications.

"We are pleased to achieve an important milestone for our company, which we expect to be the first of many such advances as we pursue FDA approval of our lead pain and anti-inflammatory product, Impracor™ and consider other potential product candidates utilizing our unique Accudel™ topical drug-delivery platform as we implement our business model," said Mark L. Baum, CEO of Imprimis.

Imprimis has selected Novum Pharmaceutical Research Services, based in Pittsburgh, PA, to conduct the study in 40 healthy human subjects, and PPD Laboratories to perform the analysis of the active drug in the blood samples. 

"We believe this study marks a major step forward to understanding the influence of different conditions on the absorption of topical ketoprofen," said Dr. Joachim Schupp, Imprimis's Chief Medical Officer. "Members of our Science and Regulatory Advisory Board did an outstanding job in assisting us with the trial protocol, culminating in the FDA clearing the protocol for initiation.  The Phase I clinics at Novum Pharmaceutical Research Services have a strong reputation for conducting pharmacokinetic and bioavailability studies," Dr. Schupp added.

"We expect the study will build on previous research that suggests the topical delivery of ketoprofen results in minimal levels of the drug in the bloodstream compared with what is known for an oral dose of the medication," said Dr.Schupp.

The study is expected to be completed during the fourth quarter of 2012.

"We are gratified to have been selected to work with Imprimis Pharmaceuticals to conduct this study for the evaluation of its lead pain product Impracor, and we are committed to the successful execution of this study, which is intended to provide data to meet FDA requirements," said Chris Hendy, Ph.D., President of Novum.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. 

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis's reports filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no  obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Mark L. Baum
Imprimis Pharmaceuticals, Inc.
(858) 433-2800


SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Names Two Experts To Its Science And Regulatory Board
2. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
3. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
4. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
5. Life Technologies Begins Shipping Ion Proton System
6. Phase 3 Clinical Trial Begins in Early Form of Dementia
7. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
8. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
9. Countdown Begins For AdvaMed 2012: The Medtech Conference
10. K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets
11. Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015 Health Gorilla ( ... Clinical Network – a secure platform for clinical data ... patients interact about and manage healthcare in the US. The ... round, for a combined total of $4.4M raised to date, ... from True Ventures , Harris Barton , ...
(Date:10/13/2015)... CARLOS, Calif. , Oct. 13, 2015   ... development advisory firm in Quantitative Systems Pharmacology (QSP)/ PhysioPD™ ... Chief Engineer, will lead a workshop at the ... 2015 in Boston, MA.  The ... in pharmaceutical drug development.  Dr. Friedrich,s workshop is entitled ...
(Date:10/13/2015)... , Oct. 13, 2015 China Jo-Jo ... " China Jo-Jo "), a leading China-based retail, wholesale ... through its own online and retail pharmacies, announced preliminary ... official branded online pharmacy through , growing ... a record 25%. China Jo-Jo,s ...
Breaking Medicine Technology:
(Date:10/13/2015)... Dallas, Texas (PRWEB) , ... October 13, 2015 ... ... network headquartered in McHenry County, Illinois with more than 59,000 emergency department visits ... department information system (EDIS) from T-System, to help improve clinical, operational and financial ...
(Date:10/13/2015)... ... ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, pain free sedation ... than 5 years. A leading cause of emergency room visits, school absences, and missed ... , Sedation dentistry provides an anxiety-free dental experience with safe and ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... World ... Driveway Snow Blanket, a snow melting invention that helps people in clearing snow away ... and will continue to grow at 3.8% per year," says Scott Cooper, CEO and ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an ESPN report published on ... teammate accidentally elbowed him in the left eye during the first day of practice ... of a series of setbacks, including a knee injury that has interfered with his ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, an award-winning and ... to introduce the latest development, ThermiVa® temperature controlled radiofrequency to the medical community. ... Obstetrics and Gynecology and a pioneer in the field of laparoscopy. On June ...
Breaking Medicine News(10 mins):